198 related articles for article (PubMed ID: 10363025)
1. Bis-benzimidazole anticancer agents: targeting human tumour helicases.
Soderlind KJ; Gorodetsky B; Singh AK; Bachur NR; Miller GG; Lown JW
Anticancer Drug Des; 1999 Feb; 14(1):19-36. PubMed ID: 10363025
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
[TBL] [Abstract][Full Text] [Related]
3. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
4. DNA alkylation by minor groove-binding N1-alkoxyalkyl-bis-benzimidazoles.
Gupta R; Huang L; Wang H; Lown JW
Anticancer Drug Des; 1995 Sep; 10(6):451-61. PubMed ID: 7575987
[TBL] [Abstract][Full Text] [Related]
5. Distribution of furamidine analogues in tumor cells: targeting of the nucleus or mitochondria depending on the amidine substitution.
Lansiaux A; Tanious F; Mishal Z; Dassonneville L; Kumar A; Stephens CE; Hu Q; Wilson WD; Boykin DW; Bailly C
Cancer Res; 2002 Dec; 62(24):7219-29. PubMed ID: 12499262
[TBL] [Abstract][Full Text] [Related]
6. Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding.
Bachur NR; Johnson R; Yu F; Hickey R; Applegren N; Malkas L
Mol Pharmacol; 1993 Nov; 44(5):1064-9. PubMed ID: 8246909
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, DNA binding, sequence preference and biological evaluation of minor groove-selective N1-alkoxyalkyl-bis-benzimidazoles.
Wang H; Gupta R; Lown JW
Anticancer Drug Des; 1994 Jun; 9(3):153-60. PubMed ID: 8031450
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles.
Yang YH; Cheng MS; Wang QH; Nie H; Liao N; Wang J; Chen H
Eur J Med Chem; 2009 Apr; 44(4):1808-12. PubMed ID: 18762358
[TBL] [Abstract][Full Text] [Related]
9. DNA minor groove binders as potential antitumor and antimicrobial agents.
Baraldi PG; Bovero A; Fruttarolo F; Preti D; Tabrizi MA; Pavani MG; Romagnoli R
Med Res Rev; 2004 Jul; 24(4):475-528. PubMed ID: 15170593
[TBL] [Abstract][Full Text] [Related]
10. DNA minor groove targeted alkylating agents based on bisbenzimidazole carriers: synthesis, cytotoxicity and sequence-specificity of DNA alkylation.
Smaill JB; Fan JY; Denny WA
Anticancer Drug Des; 1998 Dec; 13(8):857-80. PubMed ID: 10335264
[TBL] [Abstract][Full Text] [Related]
11. Helicase inhibition by anthracycline anticancer agents.
Bachur NR; Yu F; Johnson R; Hickey R; Wu Y; Malkas L
Mol Pharmacol; 1992 Jun; 41(6):993-8. PubMed ID: 1614415
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule based delivery systems for alkylating antineoplastic compounds.
Bielawski K; Bielawska A
ChemMedChem; 2008 Apr; 3(4):536-42. PubMed ID: 18157855
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
[TBL] [Abstract][Full Text] [Related]
14. Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cells.
Alpan AS; Zencir S; Zupkó I; Coban G; Réthy B; Gunes HS; Topcu Z
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):844-9. PubMed ID: 18951286
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, DNA sequence preferential alkylation and biological evaluation of N-mustard derivatives of Hoechst 33258 analogues.
Gupta R; Wang H; Huang L; Lown JW
Anticancer Drug Des; 1995 Jan; 10(1):25-41. PubMed ID: 7535056
[TBL] [Abstract][Full Text] [Related]
16. Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties: synthesis, DNA sequence specificity and biological evaluation.
Gupta R; Liu J; Xie G; Lown JW
Anticancer Drug Des; 1996 Dec; 11(8):581-96. PubMed ID: 9022747
[TBL] [Abstract][Full Text] [Related]
17. Sequence-selective targeting of long stretches of the DNA minor groove by a novel dimeric bis-benzimidazole.
Joubert A; Sun XW; Johansson E; Bailly C; Mann J; Neidle S
Biochemistry; 2003 May; 42(20):5984-92. PubMed ID: 12755600
[TBL] [Abstract][Full Text] [Related]
18. Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents.
Craigo WA; LeSueur BW; Skibo EB
J Med Chem; 1999 Aug; 42(17):3324-33. PubMed ID: 10464019
[TBL] [Abstract][Full Text] [Related]
19. Non-covalent ligand/DNA interactions: minor groove binding agents.
Nelson SM; Ferguson LR; Denny WA
Mutat Res; 2007 Oct; 623(1-2):24-40. PubMed ID: 17507044
[TBL] [Abstract][Full Text] [Related]
20. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole.
Woynarowski JM; McHugh M; Sigmund RD; Beerman TA
Mol Pharmacol; 1989 Feb; 35(2):177-82. PubMed ID: 2465485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
